Trial
NCT04377659
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
—
Condition
COVID-19
Intervention
Tocilizumab
Why stopped
Based on two large, multicenter, randomized trials showed no benefit to tocilizumab in this setting and study has been closed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-28